Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + cisplatin + carboplatin
- Development stage
- Phase 3
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of paclitaxel, cisplatin, and carboplatin. Paclitaxel is a taxane that stabilizes microtubules, preventing cancer cell division. Cisplatin and carboplatin are platinum compounds that form DNA crosslinks, interfering with DNA replication and causing cell death. This combination has been studied in clinical trials for various cancer types, including advanced ovarian cancer and endometrial cancer.
- Other names
- HIPEC with paclitaxel and cisplatinNACT with paclitaxel and carboplatin
02
Targets
MicrotubuleDNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + cisplatin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + cisplatin + carboplatin.